Table 3:

Algorithmic immunohistochemical analysis of undifferentiated carcinomas.^[16,38]

Metastatic carcinoma (SCIP approach)
Broad categorization based on: Carcinoma: PanCytokeratin + Not sarcoma: vimentin - ; Not melanoma: S100/HMB45/MelanA - ; Not hematolymphoid (lymphoma): LCA(CD45) - Differential based on coordinate immunoreactivity pattern for CK7 and CK20
CK7+/CK20+	CK7+/CK20-	CK7-/CK20+	CK7-/CK20-
Gastric AdCa (subset) Pancreatic AdCa (subset) Cholangiocarcinoma (minor subset) Ovarian mucinous Ca PAX8,MUC5-AC+ WT1, MUC2 CDX2 (variable) Urothelial Ca Uroplakin, Thrombomodulin GATA3,P63+ CK5/6 (-. ½+) Bladder AdCa Thrombomodulin+ CDX2 (variable)	Breast Ca ER/PR+ GCDFP, Mamaglobin, GATA-3+ Lung AdCa TTF1, Napsin, BAP1+ mCEA, CK5/6, p63, p40- Lung SmCC NE markers (2 of Synaptophysin, chhromogranin,CD56), TTF1, Napsin+ P63, p40- Endometrial AdCa mCEA- Vimentin, ER/PR+ Endocervical AdCa mCEA+ Vimentin, ER/PR- Cervical SqCC mCEA- P16,vimentin, ER/PR+ Ovarian (serous) Ca PAX8, PAX2, WT, mesothelin, ER/PR+ CDX2 (variable) mCEA- Ovarian (clear cell) Ca PAX8, pVHL, HNF-1β, Napsin A+ AFP, WT1, ER, GPC3- PAX2+/- Cholangiocarcinoma CK19,mCEA+ CDX2 (variable) Pancreatic AdCa DPC4,CK17+/− Maspin, S100P, MUC5AC+ pVHL− Gastric AdCa mCEA+ TTF1- CDH17+/− CDX2, MUC1, MUC5AC−/+ Esophageal AdCa mCEA, CDH17+ CDX2+/− MUC1, MUC5AC−/+ SATB2- Mesothelioma Calretinin, vimentin, CK7, CK5/6, D240, WT1 GATA3,Thrombomodulin,mesothelin+ BerEP4, B72.3, MOC31, mCEA TTF1, Napsin, p63, p40, BAP1 Thyroid Ca (Non-medullary) TTF1, Thyroglobulin,PAX8+ mCEA- Thyroid Ca (medullary) mCEA,neuroendocrine markers,calcitonin+ TTF1 (week to moderate) PAX8 (variable weak) Thyroglobulin- Salivary gland (ductal) tumors GATA3,AR,GCDFP-15+ Thymic primary CD5+/−, p63+/−, PAX8+/−, CD117+/−, Glut1+/- Renal (papillary) Ca vimentin,CA-IX,RCC(Clone PN15 anti-gp200)+ PAX2,PAX8+(>85%) Urothelial Ca(subset)	Colorectal AdCa CDX2, STAB2MUC2, mCEA, villin+ MUC5AC- Merkel cell Ca (paranuclear dot CK20) NE immunomarkers (2 of Synaptophysin, Chhromogranin,CD56), Ber/EP4+ S100,TTF1,Napsin- Gastric AdCa(subset)	Colon(medullary) SATB2+, CDH17+, CDX2,TFF3,Calretinin+/− Prostate AdCa PSA, PAP, NKX3.1, B72.3, AR+ TTF1, villin, GATA3 WT1, p63- Hepatocellular Ca pCEA and CD10 with canalicular pattern vimentin,HepPar1,Glypecan3, Arginase1+ BerEP4, CK19- Renal (clear cell) Ca PAX8, PAX2, vimentin, RCC, CD10,pVHL+ Inhibin,TTF1,mCEA- Adrenocortical Ca Vimentin, inhibin, calretinin, Melan-A, synaptophysin+ chromogranin, mCEA- Non-seminoma GCT PLAP+ EMA- Yolk sac tumor AFP+ Embryonal Ca OCT+(3/4) CD30+ Mesothelioma (subset) Lung- SmCC (subset) Gastric AdCa (subset) Head and Neck Ca

AdCa: Adenocarcinoma, Ca: Carcinoma, GCT: Germ cell tumor, HCC: Hepatocellular carcinoma, mCEA: Monoclonal carcinoembryonic antigen, NE: Neuroendocrine, pCEA: Polyclonal carcinoembryonic antigen, pVHL: von Hippel-Lindau tumor suppressor, RCC: Renal cell carcinoma, S100P: Placental S100, SmCC: Small cell carcinoma (3); SqCC: Squamous cell carcinoma; reproduced after some modifications from open access publication – Bahrami et al. Arch. Pathol. Lab. Med. 2008, 132, 326–348^[16]